<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> added to existing therapy on myocardial <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (mTG) content in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) and prevalent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) or at least one additional risk factor </plain></SENT>
<SENT sid="1" pm="."><plain>The primary endpoint, mTG content, was measured with cardiac (1)H-magnetic resonance spectroscopy </plain></SENT>
<SENT sid="2" pm="."><plain>Of the 99 randomised participants selected for the imaging sub-study, 49 (48%) had complete and interpretable spectroscopy data (age = 58 years, duration of T2D = 9.5 years; 57% women and 69% non-white) </plain></SENT>
<SENT sid="3" pm="."><plain>There was no significant change in mTG in either group (-0.1 ± 0.6% and -0.05 ± 0.8% respectively) and the changes in mTG were not associated with changes in left ventricular structure or function </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with placebo, treatment with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>